📊 NEUP Key Takeaways
Is NEUP a Good Investment? Thesis Analysis
Neuphoria Therapeutics is a pre-revenue pharmaceutical company burning cash at an unsustainable rate (-$10.2M operating cash outflow) with negative margins across all profitability metrics (-62.1% operating margin, -51.4% net margin). While the balance sheet provides 2-3 years of runway and EPS improved 98.8% YoY, the company must demonstrate significant revenue acceleration and pathway to profitability to justify continued losses.
Why Buy NEUP? Key Strengths
- Fortress balance sheet with $22.2M cash, 0.0x debt/equity ratio, and minimal liabilities ($6.9M)
- Exceptional liquidity position with 9.04x current ratio provides substantial financial flexibility
- EPS improvement trend (+98.8% YoY) indicates operational losses are narrowing
NEUP Investment Risks to Consider
- Severe cash burn (-$10.2M free cash flow) with only 2-3 years of runway at current burn rate despite strong cash reserves
- Deeply unprofitable operations with -$9.7M operating income on $15.6M revenue (-62.1% operating margin)
- Pre-commercial stage biotech with execution risk: no visible revenue growth trajectory, limited pipeline visibility, and high probability of dilutive capital raises needed
Key Metrics to Watch
- Operating cash flow trend and cash runway longevity relative to clinical trial progression
- Revenue growth acceleration and gross margins as products approach/enter commercialization
- Path to operating profitability and timeline to break-even or next major clinical milestone
NEUP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 9.04x current ratio provides a solid financial cushion.
NEUP Profitability Ratios
NEUP vs Healthcare Sector
How Neuphoria Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NEUP Overvalued or Undervalued?
Based on fundamental analysis, Neuphoria Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NEUP Balance Sheet & Liquidity
NEUP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Neuphoria Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-18.62 indicates the company is currently unprofitable.
NEUP Growth Metrics (YoY)
NEUP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.0M | -$804.8K | $-2.83 |
| Q2 2025 | $662.7K | -$804.8K | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NEUP Capital Allocation
NEUP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Neuphoria Therapeutics Inc. (CIK: 0001191070)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NEUP
What is the AI rating for NEUP?
Neuphoria Therapeutics Inc. (NEUP) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NEUP's key strengths?
Claude: Fortress balance sheet with $22.2M cash, 0.0x debt/equity ratio, and minimal liabilities ($6.9M). Exceptional liquidity position with 9.04x current ratio provides substantial financial flexibility.
What are the risks of investing in NEUP?
Claude: Severe cash burn (-$10.2M free cash flow) with only 2-3 years of runway at current burn rate despite strong cash reserves. Deeply unprofitable operations with -$9.7M operating income on $15.6M revenue (-62.1% operating margin).
What is NEUP's revenue and growth?
Neuphoria Therapeutics Inc. reported revenue of $15.6M.
Does NEUP pay dividends?
Neuphoria Therapeutics Inc. does not currently pay dividends.
Where can I find NEUP SEC filings?
Official SEC filings for Neuphoria Therapeutics Inc. (CIK: 0001191070) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NEUP's EPS?
Neuphoria Therapeutics Inc. has a diluted EPS of $-2.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NEUP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Neuphoria Therapeutics Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NEUP stock overvalued or undervalued?
Valuation metrics for NEUP: ROE of -27.1% (sector avg: 15%), net margin of -51.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NEUP stock in 2026?
Our dual AI analysis gives Neuphoria Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NEUP's free cash flow?
Neuphoria Therapeutics Inc.'s operating cash flow is $-10.2M, with capital expenditures of N/A. FCF margin is -65.4%.
How does NEUP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -51.4% (avg: 12%), ROE -27.1% (avg: 15%), current ratio 9.04 (avg: 2).